Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) ha...

 August 11, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 ( Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

 August 08, 2023 | News

Cicada Innovations Expands to Westmead Health & Innovation District with Investment NSW Support

The incubator will be the first health-focused incubator funded by the NSW government to support pre-revenue health-tech startups in bridging the gap betwe...

 August 04, 2023 | News

Peter Mac launches BindiMaps to help patients and visitors with vision impairments

The newly-installed service functions like Google Maps, but has been specifically developed to work indoors with a 10 to 20 times higher accuracy than GPS ...

 August 03, 2023 | News

NAVI Raises $2.4 Million for Breakthrough Medical Device Aiding Critically Ill Newborns

After a successful raise Navi Medical Technologies has closed a $2.4 million round of funding, which included a $700,000 lead in...

 August 03, 2023 | News

MSD and Moderna Launch Phase 3 Study for Melanoma Treatment

“As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phas...

 July 28, 2023 | News

Hummingbird Bioscience Advances HMBD-001 Phase IB Trials in Australia, Partners with Omico for Faster Clinical Development

Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung ca...

 July 27, 2023 | News

HaemaLogiX, Peter MacCallum Cancer Centre Announce Myeloma CAR-T Trial Agreement

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...

 July 26, 2023 | News

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...

 July 25, 2023 | News

RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform

Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...

 July 25, 2023 | News

ConcertAI's TeraRecon Expands Relationship with Change Healthcare for Advanced Visualization in Australia

Advanced visualization and AI leader TeraRecon, a ConcertAI company, is excited to announce an expansion of its reseller and service agreement in Aust...

 July 24, 2023 | News

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Summary Total revenue up 21% quarter-on-quarter to $120.7M driven by global product sales Positive operating cash flow ($10.8M, an improvemen...

 July 20, 2023 | News

Merck and Telix Continue Collaboration for Targeted Radiation Therapy Studies.

 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Com...

 July 19, 2023 | News

Antengene Administers First Patient in US Clinical Study of ATG-017 for Advanced Solid Tumors with Nivolumab Combination

-  ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop...

 July 18, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in